Difference between revisions of "Normative:Antibody"
Jump to navigation
Jump to search
(Created page with "==Normative== === Variants and synonyms === * * ===Definition=== <small>Source:</small> === Encyclopaedic information === <small>Source:</small> ===Examples=== <bloc...") |
(formatting) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Normative== | ==Normative== | ||
=== Encyclopaedic information === | === Encyclopaedic information === | ||
Neutralizing antibodies directed at the receptor-binding domain of SARS-CoV-2 spike protein have been evaluated as prophylactic and therapeutic agents for COVID-19. | |||
<small>Source: https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v4.4.1.pdf</small> | |||
<small>Source:</small> | |||
===Examples=== | ===Examples=== | ||
<blockquote></blockquote><small>Source:</small> | <blockquote>Transplant recipients who are hospitalized with mild to moderate COVID-19 may be considered for anti-SARS-CoV-2 monoclonal '''antibodies''' that are available through expanded access programs.</blockquote><small>Source: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf</small> | ||
===Collocations=== | ===Collocations=== | ||
* monoclonal antibodies | |||
* anti-SARS-CoV-2 antibodies | |||
* neutralizing antibodies | |||
* antibody response | |||
* antibody titers | |||
* | * | ||
| Line 26: | Line 21: | ||
===Keyness=== | ===Keyness=== | ||
* | * antibody: 150 | ||
* monoclonal antibody: 45 | |||
* anti-sars-cov-2 monoclonal antibody: 50 | |||
* neutralizing antibody: 96 | |||
* antibody titer: 582 | |||
Latest revision as of 18:45, 7 March 2022
Normative
Encyclopaedic information
Neutralizing antibodies directed at the receptor-binding domain of SARS-CoV-2 spike protein have been evaluated as prophylactic and therapeutic agents for COVID-19.
Examples
Transplant recipients who are hospitalized with mild to moderate COVID-19 may be considered for anti-SARS-CoV-2 monoclonal antibodies that are available through expanded access programs.
Source: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
Collocations
- monoclonal antibodies
- anti-SARS-CoV-2 antibodies
- neutralizing antibodies
- antibody response
- antibody titers
Keyness
- antibody: 150
- monoclonal antibody: 45
- anti-sars-cov-2 monoclonal antibody: 50
- neutralizing antibody: 96
- antibody titer: 582